Category: by reason for retraction

Hydrogen journal pulls palladium paper for data misuse

intjhydrogenenergyThe International Journal of Hydrogen Energy is retracting a 2013 article for what appears to be the misappropriation of data.

The paper,  titled “Hydrogen production by an anaerobic photocatalytic reforming using palladium nanoparticle on boron and nitrogen doped TiO2 catalysts,” was written by researchers from the Veltech Dr RR & Dr SR Technical University, in Chennai, India, and Arizona State University.

According to the abstract: Continue reading Hydrogen journal pulls palladium paper for data misuse

Holocaust paper yanked for plagiarizing

ejesPro tip: If you’re going to write a paper on giving voice to hidden words, PLEASE try not to plagiarize!

Esther Sánchez-Pardo, of Complutense University in Madrid, was the author of a 2010 article in the European Journal of English Studies titled “Who will carry the word? The threshold between unspeakability and silence in the Holocaust narratives of Charlotte Delbo and Jorge Semprun.”

The problem, it turns out, is that a couple of other authors had their words carried, but Sánchez-Pardo didn’t bother to speak their names.

According to the abstract: Continue reading Holocaust paper yanked for plagiarizing

Paper on liver failure in babies withdrawn for lab mix-up

jpgnA paper on liver failure in infants has been retracted due to a lab error, though the author contends that the paper still holds a valuable message for pediatricians — one that could save lives.

To get to that, though, we had to make it through what turns out to be an unnecessarily vague retraction notice (more on that in a moment) in the Journal of Pediatric Gastroenterology & Nutrition:
Continue reading Paper on liver failure in babies withdrawn for lab mix-up

Immunology paper retracted for inappropriate presentation but “no evidence of intentional misconduct”

immun40_4.c1.inddA paper in Immnunity has been retracted after two separate panels determined some of the figures “inappropriately presented” the data but cleared the team of wrongdoing.

However, the original data are now unavailable, according to the notice, so there’s no way to know if the paper’s conclusions are sound.

Here’s the notice for “Suppressors of Cytokine Signaling 2 and 3 Diametrically Control Macrophage Polarization”: Continue reading Immunology paper retracted for inappropriate presentation but “no evidence of intentional misconduct”

Researcher with 25 retractions covered up other fraud, says university

Shigeaki Kato
Shigeaki Kato

The Japanese endocrinology researcher Shigeaki Kato, with at least 25 retractions to his name, is alleged to have been the ringleader of a scheme to cover up other research misconduct at the University of Tokyo, his former employer, which investigated the activity.

According to the Japan Times, Kato and three other colleagues took steps to hide evidence of image manipulation in five of 51 theses between 1996 and 2011: Continue reading Researcher with 25 retractions covered up other fraud, says university

A year after ORI report, hematology journal retracts faked paper

bloodA year after an ORI report discredited the work of former University of Washington in Seattle researcher Andrew Aprikyan, one of the papers named in the report has finally been retracted.

Here’s the notice for “Impaired survival of bone marrow hematopoietic progenitor cells in cyclic neutropenia”:  Continue reading A year after ORI report, hematology journal retracts faked paper

Serial figure fakers have expression of concern upgraded to a retraction

Another retraction has appeared up for frequent fliers Jun Li, Kailun Zhang and Jiahong Xia at Huazhong Science and Technology University in Wuhan, China.

We’ve covered them twice before, for a variety of retractions, corrections, and expressions of concern.

The retraction, in Clinical and Experimental Immunology, upgrades an expression of concern published earlier this year, and is the team’s fourth.

Here’s the notice for “CCR5 blockade in combination with rapamycin prolongs cardiac allograft survival in mice”: Continue reading Serial figure fakers have expression of concern upgraded to a retraction

PLOS ONE retraction notice blames deceased author for image manipulation

A 2011 paper in PLOS ONE has been retracted due to “inappropriately assembled” images. The issues, which were highlighted in a correction in TK, are attributed to the corresponding author, Paola Palozza, who has since passed away.

Here’s the notice for “Lycopene Inhibits NF-kB-Mediated IL-8 Expression and Changes Redox and PPARγ Signalling in Cigarette Smoke–Stimulated Macrophages,” which has been cited 33 times, according to Thomson Scientific’s Web of Knowledge: Continue reading PLOS ONE retraction notice blames deceased author for image manipulation

Another Nature stem cell paper is retracted

nature 73014Another stem cell paper has been retracted from Nature, this one a highly cited 2008 study that had already been the subject of what the journal’s news section called a “furore” in 2010.

According to that 2010 news story:

The researchers behind the original work1, led by Thomas Skutella of the University of Tübingen, reported using cells from adult human testes to create pluripotent stem cells with similar properties to embryonic stem cells.

But a 2010 Brief Communication Arising called those findings into question. And now, the authors have retracted the paper. Here’s the notice for “Generation of pluripotent stem cells from adult human testis:” Continue reading Another Nature stem cell paper is retracted

MD Anderson postdoc faked results of Novartis anti-cancer compound study

jun fu
Raymond Sawaya, director of MD Anderson’s brain tumor program, presents Jun Fu with the 2014 Caroline Ross Endowment Fellowship.

A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI).

Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells,” a paper published in Cancer Research on May 15, 2013:

Continue reading MD Anderson postdoc faked results of Novartis anti-cancer compound study